版本:
中国

BRIEF-Orexigen Therapeutics announces commercialization and distributorship agreement with Bruno Farmaceutici S.p.A. for Mysimba in Italy

March 27 Orexigen Therapeutics Inc

* Orexigen Therapeutics announces commercialization and distributorship agreement with Bruno Farmaceutici S.p.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Italy

* Orexigen Therapeutics Inc- Under terms of agreement, Bruno will be responsible for all commercialization activity and expenses

* Orexigen Therapeutics Inc says Bruno expects that Mysimba will be available for patients in Italy in Q4 of this year

* Orexigen Therapeutics Inc - Orexigen Therapeutics Ireland, Bruno Farmaceutici executed a distributorship agreement for Mysimba in Italy

* Orexigen Therapeutics-Under deal co to supply Mysimba to Bruno for negotiated transfer price, upfront milestone payments at signing, first commercial sale Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐